Neurogene Inc.

Neurogene Inc.

NGNE·NASDAQ

$26.22

+0.31%
HealthcareBiotechnology

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

At a Glance

Live Snapshot
Market Cap$414.33M
EPS-4.2400
P/E Ratio-6.18
Earnings Date08/07/2026

ngne

Common Stock

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Neurogene Inc.

Neurogene Inc. Competitors Analysis of Common Stock

NGNE · NASDAQ
CompanyCommon Stock
CAGR 3Y
CAGR 5Y
CAGR 10Y
NGNE logo
Neurogene Inc.
NASDAQ:NGNE
0.00
N/AN/AN/A 
OCGN logo
Ocugen, Inc.
NASDAQ:OCGN
3.12M
6.8%9.4%34.7%
9.00K
108.0%N/AN/A
1.08M
6.2%10.9%14.9%
6.00K
14.5%14.9%N/A
1.00K
-41.5%-24.2%N/A
6.00K
81.7%N/AN/A
2.00K
N/A14.9%-66.4%
515.47M
4.5%3.5%5.0%
4.86M
-3.8%-2.2%0.5%
67.00K
2.6%10.3%N/A
Neurogene Inc.

Neurogene Inc. Fair Value Envelope

NGNE · NASDAQ

Our analysis suggests that NGNE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $26.22, this represents a potential HIDDEN relative to our calculated worth for Neurogene Inc..

Intrinsic Value
Current Price: $26.22